The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction
Open accessAbstract
BACKGROUND: Approximately 50% of patients with heart failure have a left ventricular ejection fraction of at least 45%, but no therapies have been shown to improve the outcome of these patients. Therefore, we studied the effects of irbesartan in patients with this syndrome. METHODS: We enrolled 4128 patients who were at least 60 years of age and had New York Heart Association class II, III, or IV heart failure and an ejection fraction of at least 45% and randomly assigned them to receive 300 mg of irbesartan or placebo per day. The primary composite outcome was death from any cause or hospitalization for a cardiovascular cause (heart failure, myocardial infarction, unstable angina, arrhythmia, or stroke). Secondary outcomes included death from heart failure or hospitalization for heart failure, death from any cause and from cardiovascular causes, and quality of life. RESULTS: During a mean follow-up of 49.5 months, the primary outcome occurred in 742 patients in the irbesartan group and 763 in the placebo group. Primary event rates in the irbesartan and placebo groups were 100.4 and 105.4 per 1000 patient-years, respectively (hazard ratio, 0.95; 95% confidence interval [CI], 0.86 to 1.05; P=0.35). Overall rates of death were 52.6 and 52.3 per 1000 patient-years, respectively (hazard ratio, 1.00; 95% CI, 0.88 to 1.14; P=0.98). Rates of hospitalization for cardiovascular causes that contributed to the primary outcome were 70.6 and 74.3 per 1000 patient-years, respectively (hazard ratio, 0.95; 95% CI, 0.85 to 1.08; P=0.44). There were no significant differences in the other prespecified outcomes. CONCLUSIONS: Irbesartan did not improve the outcomes of patients with heart failure and a preserved left ventricular ejection fraction. (ClinicalTrials.gov number, NCT00095238.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“once weekly subcutaneous injection with semaglutide resulted in a marked and sustained weight loss of >15% in patients who are overweight or obese.”
From The cardioprotective effects of semaglutide exceed those of dietary weight loss in mice with HFpEF (2023) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
The SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029
Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08089-3 · Cited by 5,407
Trends in Prevalence and Outcome of Heart Failure with Preserved Ejection Fraction
Owan, T., Hodge, D. O., Herges, R. M., Jacobsen, S. J., Roger, V. L., & Redfield, M. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052256 · Cited by 4,209
A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
Yusuf, S., Pfeffer, M. A., Swedberg, K., Granger, C. B., Held, P., McMurray, J. J., Michelson, E. L., Olofsson, B., & Östergren, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14285-7 · Cited by 2,994
Self-citationThe Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F. M., Remme, W. J., Cody, R. J., Castaigne, A., Pérez, A. J. P., Palensky, J., & Wittes, J. T. (2000) · Survey of Anesthesiology · doi:10.1097/00132586-200006000-00059 · Cited by 2,927
Paulus, W. J., Tschöpe, C., Sanderson, J. E., Rusconi, C., Flachskampf, F. A., Rademakers, F. E., Marino, P. N., Smiseth, O. A., Keulenaer, G. W. D., Leite-Moreira, A. F., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm037 · Cited by 2,646
Outcome of Heart Failure with Preserved Ejection Fraction in a Population-Based Study
Bhatia, R. S., Tu, J. V., Lee, D. S., Austin, P. C., Fang, J., Haouzi, A., Gong, Y., & Liu, P. P. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa051530 · Cited by 1,959
Pfeffer, M. A., Swedberg, K. B., Granger, C. B., Held, P., McMurray, J. J. V., Michelson, E. L., Olofsson, B., Östergren, J., & Yusuf, S. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14282-1 · Cited by 1,895
Self-citation
Cited by
Sorted by citations
Items 801–900 of 1,001
Correia, E. T. D. O., & Mesquita, E. T. (2022) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20210753 · Cited by 24
Martinez, C. S., Zheng, A., & Xiao, Q. (2024) · Antioxidants · doi:10.3390/antiox13111330 · Cited by 26
Volterrani, M., Hálasz, G., Adamopoulos, S. N., Agostoni, P., Butler, J., Coats, A. J. S., Solal, A. C., Doehner, W., Filippatos, G., Jankowska, E. A., et al. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad400 · Cited by 22
A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors
Siragy, H. M. (2011) · Vascular Health and Risk Management · doi:10.2147/vhrm.s15541 · Cited by 20
Zafrir, B., Paz, H., Wolff, R., Salman, N., Merhavi, D., Lewis, B. S., & Amir, O. (2010) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2010.10.004 · Cited by 20
Pharmacotherapy of Heart Failure with Preserved Ejection Fraction
Basaraba, J. E., & Barry, A. R. (2015) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1556 · Cited by 21
Novel Biomarkers in Heart Failure with Preserved Ejection Fraction
Shah, K., & Maisel, A. S. (2014) · Heart Failure Clinics · doi:10.1016/j.hfc.2014.04.005 · Cited by 21
Vicent, L., Juan Cinca, A., Vázquez, R., González‐Juanatey, J. R., Rivera, M., Segovia, J., Pascual-Figal, D. A., Bover, R., Worner, F., Delgado, J. F., et al. (2019) · Internal Medicine Journal · doi:10.1111/imj.14289 · Cited by 21
Scheffer, M., Driessen‐Waaijer, A., Hamdani, N., Landzaat, J. W. D., Jonkman, N. H., Paulus, W. J., & van Heerebeek, L. (2020) · ESC Heart Failure · doi:10.1002/ehf2.13055 · Cited by 21
Upadhya, B., Willard, J. J., Lovato, L., Rocco, M. V., Lewis, C. E., Oparil, S., Cushman, W. C., Bates, J. T., Bello, N. A., Aurigemma, G. P., et al. (2021) · Circulation Heart Failure · doi:10.1161/circheartfailure.121.008322 · Cited by 21
Age and Sex Differences in Heart Failure With Preserved Ejection Fraction
Kobak, K. A., Zarzycka, W., & Chiao, Y. A. (2022) · Frontiers in Aging · doi:10.3389/fragi.2022.811436 · Cited by 24
Targets and management of hypertension in heart failure: focusing on the stages of heart failure
Miao, H., Zou, C., Yang, S., Chia, Y. C., Minh, H. V., Sogunuru, G. P., Tay, J. C., Wang, T., Kario, K., & Zhang, Y. (2022) · Journal of Clinical Hypertension · doi:10.1111/jch.14553 · Cited by 22
Baroreflex activation as a novel therapeutic strategy for diastolic heart failure
Brandt, M. C., Madershahian, N., Velden, R., & Hoppe, U. C. (2010) · Clinical Research in Cardiology · doi:10.1007/s00392-010-0249-0 · Cited by 21
Goldberg, R. J., Gurwitz, J. H., Saczynski, J. S., Hsu, G., McManus, D. D., Magid, D. J., Smith, D. H., & Go, A. S. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.01.276 · Cited by 21
Merillon, J. P., Ennezat, P. V., Guiomard, A., Masquet-Gourgon, C., Aumont, M. C., & Gourgon, R. (2014) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2014.08.001 · Cited by 21
Air-Stable and Catalytically Active Phosphinous Acid Transition-Metal Complexes
Kurscheid, B., Belkoura, L., & Hoge, B. (2011) · Organometallics · doi:10.1021/om200697u · Cited by 21
Arterial Hypertension in Patients with Heart Failure
Dı́ez, J. (2014) · Heart Failure Clinics · doi:10.1016/j.hfc.2013.12.004 · Cited by 21
Novel strategies in diastolic heart failure
Paulus, W. J. (2010) · Heart · doi:10.1136/hrt.2009.169052 · Cited by 21
Heart failure with preserved ejection fraction
Pellicori, P., & Cleland, J. G. F. (2014) · Clinical Medicine · doi:10.7861/clinmedicine.14-6-s22 · Cited by 23
Clinical Application of Biomarkers in Heart Failure with a Preserved Ejection Fraction: A Review
Garg, A., Virmani, D., Agrawal, S., Agarwal, C., Sharma, A., Stefanini, G. G., & Kostis, J. B. (2016) · Cardiology · doi:10.1159/000450573 · Cited by 21
Novel Biomarkers for the Risk Stratification of Heart Failure with Preserved Ejection Fraction
Cypen, J., Ahmad, T., Testani, J. M., & DeVore, A. D. (2017) · Current Heart Failure Reports · doi:10.1007/s11897-017-0358-4 · Cited by 21
Gallo, G., Tocci, G., Fogacci, F., Battistoni, A., Rubattu, S. D., & Volpe, M. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.05.084 · Cited by 20
Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan
Rohde, L. E. P., Claggett, B. L., Wolsk, E., Packer, M., Zile, M. R., Swedberg, K. B., Rouleau, J. L., Pfeffer, M. A., Desai, A. S., Lund, L. H., et al. (2021) · Circulation Heart Failure · doi:10.1161/circheartfailure.120.008052 · Cited by 21
Self-citationShah, S. J., Cowie, M., Wachter, R., Szecsödy, P., Shi, V. C., Ibram, G., Hu, M., Zhao, Z., Gong, J., & Pieske, B. M. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2277 · Cited by 22
Association Between Arterial Stiffness and Heart Failure With Preserved Ejection Fraction
Chi, C., Liu, Y., Xu, Y., & Xu, D. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.707162 · Cited by 21
López, R. Q., Alegría, J. G., Escalante, M. D. M., Trujillo‐Santos, J., Villena-Ruiz, M. A., & Milla, E. P. (2011) · Medicina Clínica · doi:10.1016/j.medcli.2011.03.031 · Cited by 22
Hypertension as an Underlying Factor in Heart Failure With Preserved Ejection Fraction
Volpe, M., McKelvie, R. S., & Drexler, H. (2010) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2009.00253.x · Cited by 21
Self-citationThe Role of Irbesartan in the Treatment of Patients with Hypertension
Borghi, C., & Cicero, A. F. G. (2012) · High Blood Pressure & Cardiovascular Prevention · doi:10.2165/11632100-000000000-00000 · Cited by 21
Tschöpe, C., & Senni, M. (2019) · Heart Failure Reviews · doi:10.1007/s10741-019-09853-7 · Cited by 21
Outcomes in Patients With Heart Failure With Preserved Ejection Fraction
Kitzman, D. W. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.12.011 · Cited by 21
Maharaj, R. (2012) · Journal of the Saudi Heart Association · doi:10.1016/j.jsha.2012.01.004 · Cited by 20
Wagdy, K., & Nagy, S. (2021) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2021.17 · Cited by 23
Ageev, F. T., & Ovchinnikov, A. G. (2023) · Kardiologiia · doi:10.18087/cardio.2023.3.n2376 · Cited by 22
Angiotensin-Converting Enzyme and Heart Failure
Álvarez-Zaballos, S., & Martínez‐Sellés, M. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2807150 · Cited by 26
Matsumoto, S., Kondo, T., Yang, M., Campbell, R. T., Docherty, K. F., de Boer, R. A., Desai, A. S., Lam, C. S. P., Packer, M., Pitt, B., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.3044 · Cited by 22
Self-citationThe current best drug treatment for hypertensive heart failure with preserved ejection fraction
Rist, A., Sevre, K., Wachtell, K., Devereux, R. B., Aurigemma, G. P., Smiseth, O. A., Kjeldsen, S. E., Julius, S., Pitt, B., Burnier, M., et al. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.10.008 · Cited by 23
Osawa, K., Miyoshi, T., Oe, H., Sato, S., Nakamura, K., Kohno, K., Morita, H., Kanazawa, S., & Ito, H. (2015) · Heart and Vessels · doi:10.1007/s00380-015-0645-5 · Cited by 20
Pattern of Bladder Cancer at University Teaching Hospital, Lusaka, Zambia in the era of HIV Epidemic
Mapulanga, V. (2012) · Medical Journal of Zambia · Cited by 20
Wu, C., Lee, J., Chiang, F., Lin, L., Lin, J., Hwang, J., Tseng, C.-D., & Tsai, C. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.12.008 · Cited by 20
Hasenfuss, G. P., Anker, S. D., Bauersachs, J. K., Böhm, M., Hoppe, U. C., Pieske, B. M., von Scheidt, W., & Wachter, R. (2013) · Der Kardiologe · doi:10.1007/s12181-013-0491-6 · Cited by 21
Becher, P. M., Fluschnik, N., Blankenberg, S., & Westermann, D. (2015) · World Journal of Cardiology · doi:10.4330/wjc.v7.i9.544 · Cited by 20
Volpe, M., Tocci, G., de la Sierra, A., Kreutz, R. H., Laurent, S., Manolis, A. J., & Tsioufis, K. (2017) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-017-0239-7 · Cited by 20
Tokuhisa, H., Murai, H., Okabe, Y., Hamaoka, T., Sugimoto, H., Mukai, Y., Inoue, O., Takashima, S., Kato, T., Usui, S., et al. (2018) · Autonomic Neuroscience · doi:10.1016/j.autneu.2018.04.006 · Cited by 20
Tsujimoto, T., & Kajio, H. (2018) · European Journal of Preventive Cardiology · doi:10.1177/2047487318780035 · Cited by 20
Kato, E. T., & Kimura, T. (2020) · International Journal of Heart Failure · doi:10.36628/ijhf.2019.0013 · Cited by 21
Cui, X., Thunström, E. Ö., Dahlström, U., Zhou, J., Ge, J., & Fu, M. L. X. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12899 · Cited by 21
Hypertension as a Road to Treatment of Heart Failure with Preserved Ejection Fraction
Hicklin, H., Gilbert, O. N., Ye, F., Brooks, J., & Upadhya, B. (2020) · Current Hypertension Reports · doi:10.1007/s11906-020-01093-7 · Cited by 23
Marzak, H., Ayme‐Dietrich, E., Lawson, R., Mokni, W., Combe, R., Becker, J., Fertak, L. E., Champy, M., & Monassier, L. (2014) · Journal of Hypertension · doi:10.1097/hjh.0000000000000159 · Cited by 20
β-Blocker therapy in heart failure with preserved ejection fraction: Importance of dose and duration
Yamamoto, K. (2015) · Journal of Cardiology · doi:10.1016/j.jjcc.2015.02.004 · Cited by 20
Bronzwaer, J. G. F., & Paulus, W. J. (2009) · Current Heart Failure Reports · doi:10.1007/s11897-009-0038-0 · Cited by 20
Negi, S., Jeong, E.-M., Shukrullah, I., Veleder, E., Jones, D. P., Fan, T. M., Varadarajan, S., Danilov, S. M., Fukai, T., & Dudley, S. C. (2015) · BioMed Research International · doi:10.1155/2015/825027 · Cited by 20
Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction
Cheitlin, M. D. (2009) · Yearbook of Cardiology · doi:10.1016/s0145-4145(09)79476-6 · Cited by 20
Bermejo, J., Segovia, J., & Alfonso, F. (2009) · Revista Española de Cardiología · doi:10.1016/s0300-8932(09)70160-5 · Cited by 20
Sakata, Y., Nochioka, K., Miura, M., Takada, T., Tadaki, S., Miyata, S., Shiba, N., & Shimokawa, H. (2013) · Journal of Cardiology · doi:10.1016/j.jjcc.2013.02.011 · Cited by 20
Treatment of heart failure in the elderly: never say it's too late
Metra, M., Cas, L. D., & Massie, B. M. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehp024 · Cited by 20
Self-citationHeart Failure in Older Patients: An Update
Montalto, M., D’Ignazio, F., Camilli, S., Francesco, S. D., Fedele, M., Landi, F., & Gallo, A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14061982 · Cited by 27
Haq, M. A. U. (2014) · World Journal of Cardiology · doi:10.4330/wjc.v6.i2.67 · Cited by 19
Present and future pharmacotherapeutic agents in heart failure: an evolving paradigm
Loudon, B. L., Noordali, H., Gollop, N. D., Frenneaux, M. P., & Madhani, M. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13480 · Cited by 20
Addressing the Heterogeneity of Heart Failure in Future Randomized Trials
Iorio, A., Pozzi, A., & Senni, M. (2017) · Current Heart Failure Reports · doi:10.1007/s11897-017-0332-1 · Cited by 19
Anker, S. D., Khan, M. S., Shahid, I., Filippatos, G. S., Coats, A. J. S., & Butler, J. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2279 · Cited by 19
Cho, J. H., Leong, D. W., Cuk, N., Ebinger, J. E., Bresee, C. J., Yoon, S., Ehdaie, A., Shehata, M. M., Wang, X., Chugh, S. S., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0254641 · Cited by 19
Vaishnav, J., Yanek, L. R., Hahn, V. S., Yang, E., Trivedi, R. K., Kass, D. A., & Sharma, K. (2021) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2021.12.007 · Cited by 20
Yang, D., Zhang, Y., Yan, J. R., Liu, M. R., & An, F. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.942125 · Cited by 21
Mechanisms of current therapeutic strategies for heart failure: more questions than answers?
Khan, M. S., Shahid, I., Greene, S. J., Mentz, R. J., DeVore, A. D., & Butler, J. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac187 · Cited by 20
Why Have We Not Been Able to Demonstrate Reduced Mortality in Patients With HFmrEF/HFpEF?
Kondo, T., Henderson, A. D., Docherty, K. F., Jhund, P. S., Vaduganathan, M., Solomon, S. D., & McMurray, J. J. V. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.08.033 · Cited by 20
Self-citationMedication Management of Chronic Heart Failure in Older Adults
Alagiakrishnan, K., Banach, M., Jones, L. G., Ahmed, A., & Aronow, W. S. (2013) · Drugs & Aging · doi:10.1007/s40266-013-0105-9 · Cited by 20
Medical Therapy in Adults with Congenital Heart Disease
Book, W., & Shaddy, R. E. (2013) · Heart Failure Clinics · doi:10.1016/j.hfc.2013.09.006 · Cited by 21
Pathophysiology-based novel pharmacotherapy for heart failure with preserved ejection fraction
Konstantinou, D. M., Chatzizisis, Y. S., & Giannoglou, G. D. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.05.012 · Cited by 19
Heart failure with preserved ejection fraction
ElGuindy, A. M., & Yacoub, M. H. (2012) · Global Cardiology Science and Practice · doi:10.5339/gcsp.2012.10 · Cited by 19
Mitter, S. S., & Shah, S. J. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-015-0541-6 · Cited by 19
Heart Failure Pharmacotherapy and Supports in the Elderly - A Short Review
Shakib, S., & Clark, R. A. (2016) · Current Cardiology Reviews · doi:10.2174/1573403x12666160622102802 · Cited by 19
Campbell, R. T., Willox, G., Jhund, P. S., Hawkins, N. M., Huang, F., Petrie, M. C., & McMurray, J. J. V. (2016) · Circulation Heart Failure · doi:10.1161/circheartfailure.115.002842 · Cited by 19
Self-citationKitada, S., Kikuchi, S., Tsujino, T., Masuyama, T., & Ohte, N. (2017) · ESC Heart Failure · doi:10.1002/ehf2.12206 · Cited by 19
Yamamoto, M., Seo, Y., Ishizu, T., Nishi, I., Hamada‐Harimura, Y., Machino‐Ohtsuka, T., Sato, K., Sai, S., Nakatsukasa, T., Sugano, A., et al. (2019) · Circulation Journal · doi:10.1253/circj.cj-18-0881 · Cited by 19
Ohtsubo, T., Shibata, R., Kai, H., Okamoto, R., Kumagai, E., Kawano, H., Fujiwara, A., Kitazono, T., Murohara, T., & Arima, H. (2019) · Hypertension Research · doi:10.1038/s41440-018-0167-5 · Cited by 20
Shen, L., Jhund, P. S., Anand, I. S., Carson, P. E., Desai, A. S., Granger, C. B., Køber, L., Michel Komajda, N., McKelvie, R. S., Pfeffer, M. A., et al. (2020) · Clinical Research in Cardiology · doi:10.1007/s00392-020-01786-8 · Cited by 19
Self-citationIgarashi, Y., Chikamori, T., Hida, S., Tanaka, H., Shiba, C., Usui, Y., Hatano, T., & Yamashina, A. (2013) · Circulation Journal · doi:10.1253/circj.cj-13-0137 · Cited by 19
Petrella, R. J., & Michailidis, P. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.08.008 · Cited by 19
Pierdomenico, S. D., Pierdomenico, A. M., Coccina, F., Lapenna, D., & Porreca, E. (2016) · American Journal of Hypertension · doi:10.1093/ajh/hpw015 · Cited by 19
Cardiac troponin and outcome in decompensated heart failure with preserved ejection fraction
Thawabi, M., Hawatmeh, A., Studyvin, S., Habib, H., Shamoon, F. E., & Cohen, M. C. (2017) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2017.03.17 · Cited by 19
Long-Term Outcomes of Adults With Heart Failure by Left Ventricular Systolic Function Status
Avula, H. R., Leong, T. K., Lee, K. K., Sung, S. H., & Go, A. S. (2018) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2018.05.036 · Cited by 20
Heart Failure With Preserved Ejection Fraction: Prevention and Management
Cilia, L., Saeed, A., Ganga, H. V., & Wu, W.-C. (2019) · American Journal of Lifestyle Medicine · doi:10.1177/1559827617695219 · Cited by 18
HFpEF and sex: understanding the role of sex differences
Smereka, Y., & Ezekowitz, J. A. (2024) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2023-0403 · Cited by 24
The Role of Coronary Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction
Tzoumas, A., Tapp, D. N., Crousillat, D. R., Honigberg, M. C., Lozano, P. F. R., Aggarwal, N. R., Ebong, I., Briller, J. E., de Oliveira, G. M., Harrington, C. M., et al. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.102345 · Cited by 23
Charoenpanichkit, C., Little, W. C., Mandapaka, S., Dall’Armellina, E., Morgan, T. M., Hamilton, C. A., & Hundley, W. G. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.10.019 · Cited by 18
A New Approach to Residual Risk in Treated Hypertension—3P Screening
Struthers, A. D. (2013) · Hypertension · doi:10.1161/hypertensionaha.113.01586 · Cited by 18
Yagi, K., Imamura, T., Tada, H., Chujo, D., Liu, J., Shima, Y., Ohbatake, A., Miyamoto, Y., Okazaki, S., Ito, N., et al. (2021) · Journal of Diabetes Research · doi:10.1155/2021/8838026 · Cited by 18
Monda, V. M., Gentile, S., Porcellati, F., Satta, E., Fucili, A., Monesi, M., & Strollo, F. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02310-2 · Cited by 20
Update on Atrial Shunt Therapy for Treatment of Heart Failure
Litwin, S. E., Borlaug, B. A., Komtebedde, J., & Shah, S. J. (2022) · Structural Heart · doi:10.1016/j.shj.2022.100090 · Cited by 18
Tang, Y., & Sang, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1030642 · Cited by 18
Breaking the Cycle of Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation
Țica, O., Khamboo, W., & Kotecha, D. (2022) · Cardiac failure review · doi:10.15420/cfr.2022.03 · Cited by 18
The Cardiovascular Effects of SGLT2 Inhibitors, RAS Inhibitors, and ARN Inhibitors in Heart Failure
Ji, P., Zhang, Z., Yan, Q., Cao, H., Zhao, Y., Yang, B., & Li, J. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14298 · Cited by 17
Obesity, Preserved Ejection Fraction Heart Failure, and Left Ventricular Remodeling
Stencel, J. D., Alai, H. R., Dhore-Patil, A., Urina‐Jassir, D., & Jemtel, T. H. L. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12093341 · Cited by 20
Shin, J., Park, J. B., Kim, K., Kim, J. H., Yang, D. H., Pyun, W. B., Kim, Y. G., Kim, G., & Chae, S. C. (2015) · Clinical Hypertension · doi:10.1186/s40885-014-0014-1 · Cited by 18
Should all patients at high cardiovascular risk receive renin-angiotensin system blockers?
Volpe, M. (2011) · QJM · doi:10.1093/qjmed/hcr190 · Cited by 19
Wilson, S. R., Ghio, S., Scelsi, L., & Horn, E. M. (2012) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2012.07.007 · Cited by 18
Targeted HFpEF therapy based on matchmaking of human and animal models
Aizpurua, A. B., Schroen, B. L. M., van Bilsen, M., & van Empel, V. P. M. (2018) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00024.2018 · Cited by 20
Chung, Y. J., Choi, K. H., Lee, S. H., Shin, D., Hong, D., Park, S., Joh, H. S., Kim, H. K., Ha, S. J., Park, T. K., et al. (2022) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2022.11.014 · Cited by 19
Choi, K. H., Yang, J. H., Seo, J., Hong, D., Youn, T., Joh, H. S., Lee, S. H., Kim, D., Park, T. K., Lee, J. M., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.027581 · Cited by 18
Review: Heart failure with preserved ejection fraction in African Americans.
Shah, S. (2012) · PubMed · Cited by 18
Metadata
- Authors
- Massie, B. M., Carson, P. E., McMurray, J. J., Komajda, M., McKelvie, R., Zile, M. R., Anderson, S., Donovan, M., Iverson, E., Staiger, C., & Ptaszynska, A.
- Affiliations
- San Francisco VA Medical Center (US)
- Georgetown University (US)
- University of Glasgow (GB)
- Hamilton Health Sciences (CA)
- Medical University of South Carolina (US)
- University of Wisconsin–Madison (US)
- Bristol-Myers Squibb (United States) (US)
- Sanofi (United States) (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-12-04
- Volume
- 359
- Issue
- 23
- Pages
- 2456-2467
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2068519950
- Cited by
- 1,960
- References
- 37
- Citations by year
- 2026: 61 · 2025: 72 · 2024: 92 · 2023: 94 · 2022: 128 · 2021: 120 · 2020: 123 · 2019: 118 · 2018: 117 · 2017: 138 · 2016: 105 · 2015: 127 · 2014: 119 · 2013: 122 · 2012: 109
- FWCI
- 75.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion, other-oa)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- irbesartan, heart failure with preserved ejection fraction, angiotensin receptor blockers, cardiovascular mortality, cardiovascular hospitalization, heart failure hospitalization, quality of life, elderly patients
- MeSH terms
- Irbesartan, Adrenergic beta-Antagonists, Aged, Angiotensin-Converting Enzyme Inhibitors, Biphenyl Compounds, Cardiovascular Diseases, Drug Therapy, Combination, Female, Follow-Up Studies, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Quality of Life, Stroke Volume, Tetrazoles, Proportional Hazards Models, Treatment Failure, Angiotensin II Type 1 Receptor Blockers, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
